chlorochromate(VI) ion | 15906-70-4

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 过渡金属盐
• 英文名称: chlorochromate(VI) ion
• 英文别名: chlorochromate ion；chlorochromate
• CAS: 15906-70-4
• 化学式: ClCrO₃
• 分子量: 135.447
• InChiKey: RRPGGKMPEUCBOR-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.74
• 重原子数：
  5.0
• 可旋转键数：
  0.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.2
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  1-(4-氟苯基)戊-4-烯-1-醇 、 chlorochromate(VI) ion 在 Silica gel 、 SiO2 、 ethyl acetate heptane 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以Column chromatography (SiO2; heptane/EtOAc 4:1) gave 1-(4-fluoro-phenyl)-pent-4-en-1-one (4.67 g, 96%) as a light yellow liquid.MS (EI)的产率得到1-(4-氟苯基)-4-戊烯-1-酮
  参考文献：
  名称：

  4,5-dihydro-oxazol-2yl derivatives

  摘要：

  本发明涉及式I的化合物，其中R1、R2、X、Y和n在规范中定义，并且其药物可接受的酸盐也包括在内。本发明还提供了制备这些化合物的药物组合物和方法。这些化合物可用于治疗与微量胺相关受体的生物功能有关的疾病，这些疾病包括抑郁症、焦虑症、双相障碍、注意力缺陷多动症、应激相关疾病、精神疾病、精神分裂症、神经疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、饮食失调、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和失灵、睡眠和昼夜节律障碍以及心血管疾病。

  公开号：

  US08357712B2
• 作为试剂：
  描述：

  ent-2β-hydroxymanool 在 吡啶 、 chlorochromate(VI) ion 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以5 mg的产率得到ent-2-oxo-labda-8(17),14E-dien-15-al
  参考文献：
  名称：

  Diterpenes from Baccharis species

  摘要：

  DOI：

  10.1016/0031-9422(81)84033-2

文献信息

• Biologically active acylated amino acid derivatives
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US05620971A1

  公开（公告）日：1997-04-15

  The present invention relates to novel compounds which possess a broad range of useful biological activities. These compounds can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. They can also suppress, modify, or significantly reduce an immune response, including an autoimmune response in a mammal. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, for use in multi-drug resistant cancer therapy, and for prevention or treatment of graft rejection and various autoimmune diseases.

  本发明涉及一种新型化合物，其具有广泛的有用生物活性。这些化合物可以维持、增加或恢复细胞对治疗或预防药物的敏感性。它们也可以抑制、改变或显著减少哺乳动物的免疫反应，包括自身免疫反应。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于治疗多药耐药细胞、预防多药耐药的发展、用于多药耐药癌症治疗，以及预防或治疗移植排斥和各种自身免疫性疾病。
• 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES
  申请人：Galley Guido

  公开号：US20100029589A1

  公开（公告）日：2010-02-04

  The invention relates to compounds of formula I wherein R 1 , R 2 , X, Y, and n are defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention also provides pharmaceutical compositions and methods of manufacture of such compounds. The compounds are useful for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases are depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中R1、R2、X、Y和n在规范中定义，并且其药学上可接受的酸盐。本发明还提供了制备这种化合物的制药组合物和方法。这些化合物可用于治疗与微量胺相关受体的生物功能相关的疾病，这些疾病包括抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神障碍、精神分裂症、神经疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和失调、睡眠和昼夜节律障碍以及心血管疾病。
• Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
  申请人：Parion Sciences, Inc.

  公开号：US08163758B2

  公开（公告）日：2012-04-24

  Provided is class of sodium channel blockers. One example of such a compound is shown by the following formula: The compounds are useful for promoting hydration of mucosal surfaces and treating a variety of disease conditions.

  提供的是钠通道阻滞剂类别。其中一个化合物的示例如下所示：这些化合物有助于促进黏膜表面的水合作用，并治疗各种疾病。
• COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B
  申请人：Lee Amy C.H.

  公开号：US20110195127A1

  公开（公告）日：2011-08-11

  The present invention provides compositions and methods for the delivery of interfering RNAs that silence APOB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

  本发明提供了一种将干扰RNA传递到肝细胞以沉默APOB表达的组合物和方法。特别地，核酸-脂质颗粒提供了核酸的有效封装和封装核酸的有效传递到体内细胞的方法。本发明的组合物非常有效，因此可以在相对较低的剂量下有效地降低APOB。此外，与先前已知的组合物和方法相比，本发明的组合物和方法毒性较小，具有更大的治疗指数。
• COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES
  申请人：Lin Paulo J.C.

  公开号：US20120264810A1

  公开（公告）日：2012-10-18

  Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are described In particular embodiments, the methods of the invention include contacting a cell with a lipid particle and a compound that binds a Na+/K+ ATPase to enhance uptake of the lipid particle b\ the cell Related compositions useful in practicing methods include lipid particles comprising a conjugated compound that enhances uptake of the lipid particles b\ the cell The methods and compositions are useful in delivering a therapeutic agent to a cell, e g for the treatment of a disease or disorder in a subject

  本发明涉及用于增强细胞对脂质粒子摄取的组合物、方法和化合物。在特定实施例中，本发明的方法包括将脂质粒子和结合Na+/K+ ATPase的化合物与细胞接触，以增强细胞对脂质粒子的摄取。相关的组合物包括含有增强细胞对脂质粒子摄取的共轭化合物的脂质粒子。该方法和组合物可用于将治疗剂送达到细胞中，例如用于治疗受体中的疾病或疾病的治疗。